Eli Lilly (NYSE:LLY) has quickly emerged as one of Wall Street's biggest winners, fueled by explosive demand for its new generation of weight-loss and diabetes treatments. The company's GLP-1 drugs, including Mounjaro and the newly approved Zepbound, have turned into blockbuster products, generating billions in sales and reshaping the pharmaceutical landscape. As a result, Eli Lilly's stock surged more than 50% year-to-date in 2024.